As the Lyme epidemic continues to grow, conventional medicine is gradually coming to recognize chronic Lyme disease as a valid condition requiring strategic intervention. Also known as Post-Treatment Lyme Disease Syndrome (PTLDS), chronic Lyme involves ongoing inflammation and continued/increasing Lyme symptoms, after undergoing standard antibiotic treatment for Lyme disease.
Patients struggling with PTLDS often endure a multitude of persistent symptoms, including:
- Joint and muscle pain
- Brain fog Fatigue
- Sleep disturbances
- Digestive issues
- Immune suppression
In recent years, physicians and researchers have acknowledged that PTLDS patients may have high levels of inflammation. However, the specific location and nature of the inflammation were unknown, until recently.
Thanks to a relatively new brain imaging technique, researchers at Johns Hopkins discovered that PTLDS patients have significant brain inflammation, compared to healthy controls. Using a specialized form of PET scan imaging, the researchers found that levels of a specific marker of brain inflammation—TSPO (translocator protein)— were elevated in PTLDS patients. This marker was active across multiple regions of the brains of PTLDS patients, indicating widespread inflammation rather than one specific area.
PTLDS Symptoms can Persist for Decades
These findings, published December 2018 in the Journal of Neuroinflammation, are important because they help to substantiate and clarify the processes behind the ongoing symptoms PTLDS patients may experience, sometimes for decades, after treating an infection.
Addressing neuro-inflammation with targeted therapies is a critical strategy for reducing chronic Lyme symptoms, and represents a fundamental cornerstone in integrative Lyme treatment. Symptoms such as brain fog, depression, sleep disturbances, and even musculoskeletal pain, may benefit from a significant reduction in neuroinflammation.
As researchers continue to study post-treatment Lyme disease, we can expect novel new therapies to emerge, along with greater recognition of this increasingly common condition.
Botanical Support Against Ticks and other Vectors
For optimal immune support against exposure to ticks and other vectors, ecoNugenics recommends MycoTick Shield. This unique medicinal mushroom formula is designed for those seeking immune, neurological, and overall support following exposure to ticks and related vectors.*
MycoTick Shield is formulated with four medicinal mushroom species, cultivated on a blend of immune-supportive botanicals. This unique growing method fortifies the beneficial properties of the mushrooms, resulting in broad-spectrum immune and total-body health benefits. MycoTick Shield helps to balance immune activity, promote mental clarity, aid detoxification, and support a healthy microbiome—offering powerful support against common vector-borne concerns, safely and naturally.*
MycoTic Shield is a targeted mushroom formula that provides a broad-spectrum of benefits to help optimize and balance immune activity, support energy production, restore detox pathways, balance the microbiome and promote overall wellness.*